{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:15:55Z","timestamp":1789719355742,"version":"4.0.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["(\u201cMildred-Scheel\u201d professorship"],"award-info":[{"award-number":["(\u201cMildred-Scheel\u201d professorship"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013060","name":"European Molecular Biology Laboratory","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010441","name":"University of Heidelberg | Medizinischen Fakult\u00e4t Heidelberg, Universit\u00e4t Heidelberg","doi-asserted-by":"publisher","award":["Physician Scientist Program"],"award-info":[{"award-number":["Physician Scientist Program"]}],"id":[{"id":"10.13039\/501100010441","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jose Carreras Leuk\u00e4mie Stiftung"},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["TRANSCAN IV (GCL-CLL)"],"award-info":[{"award-number":["TRANSCAN IV (GCL-CLL)"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004361","name":"Krebsliga Schweiz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004361","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Monique Dornonville de la Cour - Stiftung CRC funding program der UZH CRPP \u201cNext Generation Drug Response Profiling for Personalized Cancer Care\u201c"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Drug combinations that target critical pathways are a mainstay of cancer care. To improve current approaches to combination treatment of chronic lymphocytic leukemia (CLL) and gain insights into the underlying biology, we studied the effect of 352 drug combination pairs in multiple concentrations by analysing ex vivo drug response of 52 primary CLL samples, which were characterized by \u201comics\u201d profiling. Known synergistic interactions were confirmed for B-cell receptor (BCR) inhibitors with Bcl-2 inhibitors and with chemotherapeutic drugs, suggesting that this approach can identify clinically useful combinations. Moreover, we uncovered synergistic interactions between BCR inhibitors and afatinib, which we attribute to BCR activation by afatinib through BLK upstream of BTK and PI3K. Combinations of multiple inhibitors of BCR components (e.g., BTK, PI3K, SYK) had effects similar to the single agents. While PI3K and BTK inhibitors produced overall similar effects in combinations with other drugs, we uncovered a larger response heterogeneity of combinations including PI3K inhibitors, predominantly in CLL with mutated IGHV, which we attribute to the target\u2019s position within the BCR-signaling pathway. Taken together, our study shows that drug combination effects can be effectively queried in primary cancer cells, which could aid discovery, triage and clinical development of drug combinations.<\/jats:p>","DOI":"10.1038\/s41375-020-0846-5","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T15:06:34Z","timestamp":1589382394000},"page":"2934-2950","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies"],"prefix":"10.1038","volume":"34","author":[{"given":"Marina","family":"Lukas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8397-3515","authenticated-orcid":false,"given":"Britta","family":"Velten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leopold","family":"Sellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Tomska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"H\u00fcellein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Walther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Muley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Ole\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Jethwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanibal","family":"Bohnenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7890-9845","authenticated-orcid":false,"given":"Thorsten","family":"Zenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,13]]},"reference":[{"key":"846_CR1","doi-asserted-by":"crossref","first-page":"4313","DOI":"10.1182\/blood-2011-06-338855","volume":"118","author":"FK Stevenson","year":"2011","unstructured":"Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood. 2011;118:4313\u201320.","journal-title":"Blood."},{"key":"846_CR2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2013.358","volume":"28","author":"S Cheng","year":"2014","unstructured":"Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia. 2014;28:649\u201357.","journal-title":"Leukemia."},{"key":"846_CR3","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SEM Herman","year":"2011","unstructured":"Herman SEM, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287\u201396.","journal-title":"Blood."},{"key":"846_CR4","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1182\/blood-2014-02-548610","volume":"123","author":"SEM Herman","year":"2014","unstructured":"Herman SEM, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib inhibits BCR and NF-\u03baB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL. Blood. 2014;123:3286\u201395.","journal-title":"Blood."},{"key":"846_CR5","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MFM De Rooij","year":"2012","unstructured":"De Rooij MFM, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590\u20134.","journal-title":"Blood."},{"key":"846_CR6","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182\u20139.","journal-title":"Blood."},{"key":"846_CR7","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood-2013-06-511154","volume":"123","author":"SA Rushworth","year":"2014","unstructured":"Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton\u2019s tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood. 2014;123:1229\u201338.","journal-title":"Blood."},{"key":"846_CR8","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1586\/17474086.2014.951323","volume":"7","author":"N Shah","year":"2014","unstructured":"Shah N, Hutchinson C, Rule S. Ibrutinib for the treatment of mantle cell lymphoma. Expert Rev Hematol. 2014;7:521\u201331.","journal-title":"Expert Rev Hematol."},{"key":"846_CR9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, et al. Pharmacological and genomic profiling identifies NF-\u03baB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20:87\u201392.","journal-title":"Nat Med"},{"key":"846_CR10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1475-2867-14-32","volume":"14","author":"X Zheng","year":"2014","unstructured":"Zheng X, Ding N, Song Y, Feng L, Zhu J. Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment. Cancer Cell Int. 2014;14:32.","journal-title":"Cancer Cell Int."},{"key":"846_CR11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32\u201342.","journal-title":"N Engl J Med."},{"key":"846_CR12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(13)70513-8","volume":"15","author":"S O\u2019Brien","year":"2014","unstructured":"O\u2019Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b\/2 trial. Lancet Oncol. 2014;15:48\u201358.","journal-title":"Lancet Oncol."},{"key":"846_CR13","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl Wojciech Jurczak BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med."},{"key":"846_CR14","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood-2010-02-271171","volume":"116","author":"SEM Herman","year":"2010","unstructured":"Herman SEM, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-\u03b4 inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010;116:2078\u201388.","journal-title":"Blood."},{"key":"846_CR15","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","volume":"118","author":"J Hoellenriegel","year":"2011","unstructured":"Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118:3603\u201312.","journal-title":"Blood."},{"key":"846_CR16","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014;370:2286\u201394.","journal-title":"N Engl J Med."},{"key":"846_CR17","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/bjh.12895","volume":"166","author":"CV Hutchinson","year":"2014","unstructured":"Hutchinson CV, Dyer MJS. Breaking good: the inexorable rise of BTK inhibitors in the treatment of chronic lymphocytic leukaemia. Br J Haematol. 2014;166:12\u201322.","journal-title":"Br J Haematol."},{"key":"846_CR18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3109\/10428194.2013.803226","volume":"55","author":"JR Brown","year":"2014","unstructured":"Brown JR. Ibrutinib in chronic lymphocytic leukemia and B cell malignancies. Leuk Lymphoma. 2014;55:263\u20139.","journal-title":"Leuk Lymphoma."},{"key":"846_CR19","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood-2013-11-535047","volume":"123","author":"JR Brown","year":"2014","unstructured":"Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110\u03b4, for relapsed\/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390\u20137.","journal-title":"Blood."},{"key":"846_CR20","first-page":"224","volume":"12","author":"SY Ng","year":"2014","unstructured":"Ng SY, Davids MS. Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-hodgkin lymphoma. Clin Adv Hematol Oncol. 2014;12:224\u20139.","journal-title":"Clin Adv Hematol Oncol."},{"key":"846_CR21","doi-asserted-by":"crossref","first-page":"4990","DOI":"10.18632\/oncotarget.2071","volume":"5","author":"SA Ezell","year":"2014","unstructured":"Ezell SA, Mayo M, Bihani T, Tepsuporn S, Wang S, Passino M, et al. Synergistic induction of apoptosis by combination of BTK and dual mTORC1\/2 inhibitors in diffuse large B cell lymphoma. Oncotarget. 2014;5:4990\u20135001.","journal-title":"Oncotarget."},{"key":"846_CR22","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1073\/pnas.1311846111","volume":"111","author":"LA Mathews Griner","year":"2014","unstructured":"Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci USA. 2014;111:2349\u201354.","journal-title":"Proc Natl Acad Sci USA"},{"key":"846_CR23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ccr.2012.05.024","volume":"21","author":"Y Yang","year":"2012","unstructured":"Yang Y, Shaffer AL, Emre NCT, Ceribelli M, Zhang M, Wright G, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 2012;21:723\u201337.","journal-title":"Cancer Cell."},{"key":"846_CR24","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/nrc4015","volume":"15","author":"AA Friedman","year":"2015","unstructured":"Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nat Rev Cancer. 2015;15:747\u201356.","journal-title":"Nat Rev Cancer"},{"key":"846_CR25","doi-asserted-by":"crossref","first-page":"4403","DOI":"10.1182\/blood-2008-08-173310","volume":"113","author":"M Vogler","year":"2009","unstructured":"Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJS, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113:4403\u201313.","journal-title":"Blood"},{"key":"846_CR26","doi-asserted-by":"crossref","first-page":"70623","DOI":"10.18632\/oncotarget.12139","volume":"7","author":"R Voltan","year":"2016","unstructured":"Voltan R, Rimondi E, Melloni E, Rigolin GM, Casciano F, Arcidiacono MV, et al. Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia. Oncotarget. 2016;7:70623\u201338.","journal-title":"Oncotarget."},{"key":"846_CR27","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2015-01-621391","volume":"125","author":"ZA Hing","year":"2015","unstructured":"Hing ZA, Mantel R, Beckwith KA, Guinn D, Williams E, Smith LL, et al. Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. Blood. 2015;125:3128\u201332.","journal-title":"Blood."},{"key":"846_CR28","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","volume":"21","author":"F Cervantes-Gomez","year":"2015","unstructured":"Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2015;21:3705\u201315.","journal-title":"Clin Cancer Res."},{"key":"846_CR29","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1182\/blood-2014-12-619163","volume":"125","author":"MFM De Rooij","year":"2015","unstructured":"De Rooij MFM, Kuil A, Kater AP, Kersten MJ, Pals ST, Spaargaren M. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood. 2015;125:2306\u20139.","journal-title":"Blood."},{"key":"846_CR30","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380:2095\u2013103.","journal-title":"N Engl J Med."},{"key":"846_CR31","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K, Mu\u00f1oz-Vicente S, Yates FJ, Bishop R, et al. Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37:2722\u20139.","journal-title":"J Clin Oncol."},{"key":"846_CR32","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(14)70335-3","volume":"15","author":"JA Burger","year":"2014","unstructured":"Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090\u20139.","journal-title":"Lancet Oncol."},{"key":"846_CR33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997\u20131007.","journal-title":"N Engl J Med."},{"key":"846_CR34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"A Chanan-Khan","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200\u201311.","journal-title":"Lancet Oncol."},{"key":"846_CR35","doi-asserted-by":"crossref","first-page":"e419","DOI":"10.1016\/S2352-3026(19)30104-8","volume":"6","author":"MS Davids","year":"2019","unstructured":"Davids MS, Brander DM, Kim HT, Tyekucheva S, Bsat J, Savell A, et al. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. Lancet Haematol. 2019;6:e419\u201328.","journal-title":"Lancet Haematol."},{"key":"846_CR36","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/s41589-018-0205-2","volume":"15","author":"C Schmidl","year":"2019","unstructured":"Schmidl C, Vladimer GI, Rendeiro AF, Schnabl S, Krausgruber T, Taubert C, et al. Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. Nat Chem Biol. 2019;15:232\u201340.","journal-title":"Nat Chem Biol."},{"key":"846_CR37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1172\/JCI93801","volume":"128","author":"S Dietrich","year":"2018","unstructured":"Dietrich S, Ole\u015b M, Lu J, Sellner L, Anders S, Velten B, et al. Drug-perturbation-based stratification of blood cancer. J Clin Investig. 2018;128:427\u201345.","journal-title":"J Clin Investig."},{"key":"846_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2404457","volume":"21","author":"P Ghia","year":"2007","unstructured":"Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stilgenbauer S, Stevenson F, et al. ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia. 2007;21:1\u20133.","journal-title":"Leukemia."},{"key":"846_CR39","first-page":"93","volume":"41","author":"MC Berenbaum","year":"1989","unstructured":"Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41:93\u2013141.","journal-title":"Pharmacol Rev."},{"key":"846_CR40","doi-asserted-by":"crossref","first-page":"e00149","DOI":"10.1002\/prp2.149","volume":"3","author":"J Foucquier","year":"2015","unstructured":"Foucquier J, Guedj M. Analysis of drug combinations: current methodological landscape. Pharmacol Res Perspect. 2015;3:e00149.","journal-title":"Pharmacol Res Perspect."},{"key":"846_CR41","doi-asserted-by":"crossref","first-page":"e67904","DOI":"10.1371\/journal.pone.0067904","volume":"8","author":"SM Geary","year":"2013","unstructured":"Geary SM, Lemke CD, Lubaroff DM, Salem AK. The combination of a low-dose chemotherapeutic agent, 5-fluorouracil, and an adenoviral tumor vaccine has a synergistic benefit on survival in a tumor model system. PLoS ONE. 2013;8:e67904.","journal-title":"PLoS ONE."},{"key":"846_CR42","first-page":"331","volume":"47","author":"WR Greco","year":"1995","unstructured":"Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995;47:331\u201385.","journal-title":"Pharmacol Rev."},{"key":"846_CR43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/msb4100116","volume":"3","author":"J Leh\u00e1r","year":"2007","unstructured":"Leh\u00e1r J, Zimmermann GR, Krueger AS, Molnar RA, Ledell JT, Heilbut AM, et al. Chemical combination effects predict connectivity in biological systems. Mol Syst Biol. 2007;3:80.","journal-title":"Mol Syst Biol."},{"key":"846_CR44","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Ser B."},{"key":"846_CR45","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.csbj.2015.09.001","volume":"13","author":"B Yadav","year":"2015","unstructured":"Yadav B, Wennerberg K, Aittokallio T, Tang J. Searching for drug synergy in complex dose-response landscapes using an interaction potency model. Comput Struct Biotechnol J. 2015;13:504\u201313.","journal-title":"Comput Struct Biotechnol J."},{"key":"846_CR46","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/ng.3488","volume":"48","author":"CC Oakes","year":"2016","unstructured":"Oakes CC, Seifert M, Assenov Y, Gu L, Przekopowitz M, Ruppert AS, et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat Genet. 2016;48:253\u201364.","journal-title":"Nat Genet."},{"key":"846_CR47","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1200\/JCO.2011.34.7898","volume":"30","author":"AW Roberts","year":"2012","unstructured":"Roberts AW, Seymour JF, Brown JR, Wierda WG, Kipps TJ, Khaw SL, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol. 2012;30:488\u201396.","journal-title":"J Clin Oncol."},{"key":"846_CR48","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson WH, O\u2019Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010;11:1149\u201359.","journal-title":"Lancet Oncol."},{"key":"846_CR49","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19:202\u20138.","journal-title":"Nat Med."},{"key":"846_CR50","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood."},{"key":"846_CR51","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1182\/blood-2014-09-585869","volume":"125","author":"JR Brown","year":"2015","unstructured":"Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, et al. The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015;125:2915\u201322.","journal-title":"Blood."},{"key":"846_CR52","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40265-013-0170-8","volume":"74","author":"GM Keating","year":"2014","unstructured":"Keating GM. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer. Drugs. 2014;74:207\u201321.","journal-title":"Drugs"},{"key":"846_CR53","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.391","volume":"5","author":"RF Dielschneider","year":"2014","unstructured":"Dielschneider RF, Xiao W, Yoon JY, Noh E, Banerji V, Li H, et al. Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling. Cell Death Dis. 2014;5:e1439.","journal-title":"Cell Death Dis."},{"key":"846_CR54","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","volume":"29","author":"MI Davis","year":"2011","unstructured":"Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, Pallares G, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011;29:1046\u201351.","journal-title":"Nat Biotechnol."},{"key":"846_CR55","doi-asserted-by":"crossref","first-page":"eaan4368","DOI":"10.1126\/science.aan4368","volume":"358","author":"S Klaeger","year":"2017","unstructured":"Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig P-A, et al. The target landscape of clinical kinase drugs. Science. 2017;358:eaan4368.","journal-title":"Science."},{"key":"846_CR56","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1182\/blood-2005-02-0488","volume":"106","author":"K Stegmaier","year":"2005","unstructured":"Stegmaier K, Corsello SM, Ross KN, Wong JS, DeAngelo DJ, Golub TR. Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood. 2005;106:2841\u20138.","journal-title":"Blood."},{"key":"846_CR57","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ccr.2009.08.018","volume":"16","author":"CK Hahn","year":"2009","unstructured":"Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, et al. Proteomic and genetic approaches identify syk as an AML target. Cancer Cell. 2009;16:281\u201394.","journal-title":"Cancer Cell."},{"key":"846_CR58","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood.V110.11.209.209","volume":"110","author":"CK Hahn","year":"2007","unstructured":"Hahn CK, Ross KN, Kakoza RM, Carr SA, Du J, Ong S-E, et al. Syk is a new target for AML differentiation. Blood. 2007;110:209.","journal-title":"Blood."},{"key":"846_CR59","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.3109\/10428194.2015.1032963","volume":"56","author":"K Crassini","year":"2015","unstructured":"Crassini K, Stevenson WS, Mulligan SP, Best OG. The MEK1\/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leuk Lymphoma. 2015;56:3407\u201317.","journal-title":"Leuk Lymphoma."},{"key":"846_CR60","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","volume":"168","author":"X Zhao","year":"2015","unstructured":"Zhao X, Bodo J, Sun D, Durkin L, Lin J, Smith MR, et al. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015;168:765\u20138.","journal-title":"Br J Haematol."},{"key":"846_CR61","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/10428194.2017.1349899","volume":"59","author":"M Schaffer","year":"2018","unstructured":"Schaffer M, Chaturvedi S, Davis C, Aquino R, Stepanchick E, Versele M, et al. Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen. Leuk Lymphoma. 2018;59:931\u201340.","journal-title":"Leuk Lymphoma."},{"key":"846_CR62","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/leu.2017.321","volume":"32","author":"VK Patel","year":"2018","unstructured":"Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, et al. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018;32:920\u201330.","journal-title":"Leukemia."},{"key":"846_CR63","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/annonc\/mdw131","volume":"27","author":"E Gaudio","year":"2016","unstructured":"Gaudio E, Tarantelli C, Kwee I, Barassi C, Bernasconi E, Rinaldi A, et al. Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. Ann Oncol. 2016;27:1123\u20138.","journal-title":"Ann Oncol."},{"key":"846_CR64","doi-asserted-by":"crossref","first-page":"e0200725","DOI":"10.1371\/journal.pone.0200725","volume":"13","author":"K Faia","year":"2018","unstructured":"Faia K, White K, Murphy E, Proctor J, Pink M, Kosmider N, et al. The phosphoinositide-3 kinase (PI3K)-\u03b4,\u03b3 inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies. PLoS ONE. 2018;13:e0200725.","journal-title":"PLoS ONE."},{"key":"846_CR65","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2007-12-127688","volume":"112","author":"A Guarini","year":"2008","unstructured":"Guarini A, Chiaretti S, Tavolaro S, Maggio R, Peragine N, Citarella F, et al. BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgVH unmutated chronic lymphocytic leukemia (CLL) cells. Blood. 2008;112:782\u201392.","journal-title":"Blood."},{"key":"846_CR66","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.18632\/oncotarget.6727","volume":"7","author":"A Guo","year":"2016","unstructured":"Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, et al. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget. 2016;7:4598\u2013610.","journal-title":"Oncotarget."},{"key":"846_CR67","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2002-06-1822","volume":"101","author":"S Lanham","year":"2003","unstructured":"Lanham S, Hamblin T, Oscier D, Ibbotson R, Stevenson F, Packham G. Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. Blood. 2003;101:1087\u201393.","journal-title":"Blood."}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0846-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0846-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0846-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:03:30Z","timestamp":1722888210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0846-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,13]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["846"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0846-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,13]]},"assertion":[{"value":"8 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"LS is currently a full-time employee of Takeda Pharma Vertrieb GmbH & Co. KG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}